Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.

With funding from charity Kidney Research UK, Dr Carl May from Bristol Medical School and his team have identified a new treatment pathway for patients with non-genetic (idiopathic) nephrotic syndrome ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

DelveInsight's comprehensive analysis reveals the Nephrotic Syndrome therapeutics market reached USD 401 million in 2022 across the 7MM, with emerging therapies including FDA-approved Furoscix and ...

In a small observational study, telitacicept use was associated with improvement in renal and hematologic parameters in patients with lupus nephritis and nephrotic syndrome. Telitacicept use is ...

For very young children with nephrotic syndrome, longer initial treatment with prednisone didn't offer much benefit, a researcher reported. In a randomized controlled trial of 172 patients ages 1 to 4 ...

Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker released in response to tubular injury, may serve as a noninvasive tool for measuring kidney injury. A new systematic review and ...

DelveInsight's “Nephrotic Syndrome Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Nephrotic Syndrome pipeline landscape. It covers the ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

(MENAFN- GetNews) DelveInsight's comprehensive analysis reveals the Nephrotic Syndrome therapeutics market reached USD 401 million in 2022 across the 7MM, with emerging therapies including ...